U.S. markets open in 52 minutes
  • S&P Futures

    4,260.75
    -20.25 (-0.47%)
     
  • Dow Futures

    33,568.00
    -150.00 (-0.44%)
     
  • Nasdaq Futures

    13,540.75
    -37.00 (-0.27%)
     
  • Russell 2000 Futures

    2,004.00
    -12.90 (-0.64%)
     
  • Crude Oil

    87.31
    -4.78 (-5.19%)
     
  • Gold

    1,798.10
    -17.40 (-0.96%)
     
  • Silver

    20.25
    -0.45 (-2.19%)
     
  • EUR/USD

    1.0207
    -0.0050 (-0.49%)
     
  • 10-Yr Bond

    2.7950
    -0.0540 (-1.90%)
     
  • Vix

    20.87
    +0.67 (+3.32%)
     
  • GBP/USD

    1.2094
    -0.0044 (-0.37%)
     
  • USD/JPY

    132.7470
    -0.7330 (-0.55%)
     
  • BTC-USD

    24,115.83
    -403.78 (-1.65%)
     
  • CMC Crypto 200

    572.13
    +0.85 (+0.15%)
     
  • FTSE 100

    7,473.33
    -27.56 (-0.37%)
     
  • Nikkei 225

    28,871.78
    +324.80 (+1.14%)
     

CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
CRISPR Therapeutics AG
CRISPR Therapeutics AG

ZUG, Switzerland and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on Wednesday, June 15, 2022, at 9:20 a.m. Pacific Time (PT).

A live webcast of the presentation will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.gcs-web.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR Therapeutics

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR THERAPEUTICS® word mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG. All other trademarks and registered trademarks are the property of their respective owners.

Investor Contact:
Susan Kim
+1-617-307-7503
susan.kim@crisprtx.com

Media Contact:
Rachel Eides
+1-617-315-4493
rachel.eides@crisprtx.com